Margeti Chrysoula, Kazakos Georgios, Skampardonis Vassilis, Galatos Apostolos D, Zacharopoulou Theodora, Tsioli Vassiliki, Loukopoulos Epameinondas, Tyrnenopoulou Panagiota, Papatsiros Vasileios G, Flouraki Eugenia
Clinic of Surgery, Faculty of Veterinary Medicine, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece.
Companion Animal Clinic, School of Veterinary Medicine, Aristotle University of Thessaloniki, 54627 Thessaloniki, Greece.
Vet Sci. 2024 Apr 25;11(5):186. doi: 10.3390/vetsci11050186.
Dexmedetomidine is an a-agonist commonly used in veterinary practice. Occasionally, the administered dose of dexmedetomidine may result in insufficient sedation, and an additional dose or drug may be required. The sedative effects of seven different drugs administered at subsequent time points after an initial, insufficient dose of dexmedetomidine were evaluated. Seven adult cats participated in this crossover, blind, randomised study. The groups consisted of two consecutive doses of dexmedetomidine (15 + 10 μg/kg) (DD) or a dose of dexmedetomidine (15 μg/kg) followed by either NS 0.9% (DC-control group), tramadol 2 mg/kg (DT), butorphanol 0.2 mg/kg (DBT), buprenorphine 20 μg/kg (DBP), ketamine 2 mg/kg (DK), or midazolam 0.1 mg/kg (DM). Sedation was evaluated using the Grint sedation scale. In all groups, atipamezole was administered at the end of the evaluation, and recovery was assessed using the Lozano and Sams recovery scales. The DC and DM groups exhibited minimal sedative effects. The maximum sedative effect was observed in the DD and DK groups, while sedation in the DD and DK groups was significantly higher compared to the DC group. Recovery in all groups was uneventful, except in the DM group, where it was prolonged and difficult, although no statistically significant difference was detected. Therefore, insufficient sedation with dexmedetomidine can be enhanced by a subsequent dose of dexmedetomidine, ketamine, or butorphanol, whereas the addition of midazolam reduces sedation and prolongs recovery.
右美托咪定是一种常用于兽医临床的α受体激动剂。偶尔，所给予的右美托咪定剂量可能导致镇静不足，可能需要额外的剂量或药物。评估了在初始剂量不足的右美托咪定之后的后续时间点给予的七种不同药物的镇静效果。七只成年猫参与了这项交叉、盲法、随机研究。分组包括连续两剂右美托咪定（15 + 10 μg/kg）（DD组），或一剂右美托咪定（15 μg/kg）后接着给予0.9%生理盐水（DC对照组）、曲马多2 mg/kg（DT组）、布托啡诺0.2 mg/kg（DBT组）、丁丙诺啡20 μg/kg（DBP组）、氯胺酮2 mg/kg（DK组）或咪达唑仑0.1 mg/kg（DM组）。使用格林特镇静量表评估镇静情况。在所有组中，在评估结束时给予阿替美唑，并使用洛萨诺和萨姆斯恢复量表评估恢复情况。DC组和DM组表现出最小的镇静效果。在DD组和DK组中观察到最大的镇静效果，并且DD组和DK组的镇静程度显著高于DC组。除了DM组恢复时间延长且困难外，所有组的恢复过程均顺利，尽管未检测到统计学上的显著差异。因此，右美托咪定镇静不足可通过后续给予右美托咪定、氯胺酮或布托啡诺增强，而添加咪达唑仑会降低镇静并延长恢复时间。
